Results 1 - 5 of 15 for: "rifaximin systemic"
Refine your search:
All results

Rifaximin
Rifaximin Pronunciation: (riff-AX-ih-min) Class: Anti-infective agent Trade Names: Xifaxan - Tablets 200 mg Pharmacology Inhibits bacterial RNA synthesis....
A-Z Drug Facts (Facts & Comparisons) · More like this · Add to my drug list

Xifaxan
Xifaxan Generic Name: rifaximin Dosage Form: Tablets Xifaxan Description Xifaxan Tablets contain rifaximin, a semi-synthetic, nonsystemic antibiotic. The chemical name for rifaximin...
Professional Monographs (FDA) · More like this

Salix Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review Designation For Rifaximin NDA For the Maintenance of Remission of Hepatic Encephalopathy
...the Food and Drug Administration (FDA) has accepted for filing and designated for Priority Review the Company's New Drug Application (NDA) for rifaximin tablets 550 mg for the maintenance of remission of hepatic encephalopathy (HE). Additionally, the FDA has informed the Company of its plan to...
New Drug Applications (FDA) · More like this

Salix Presents New Rifaximin Phase IIb Data Demonstrating Significant And Sustained Improvement in Diarrhea-Associated Irritable Bowel Syndrome (d-IBS)
...DIEGO, CA - May 20, 2008 - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced findings from two analyses of the Phase IIb clinical trial of rifaximin, its non-absorbed, gut-selective antibiotic for the treatment of patients with diarrhea-associated irritable bowel syndrome (d-IBS). Data presented...
Clinical Trial Results (FDA) · More like this

Salix Pharmaceuticals Announces Statistically Significant Results for Both the Primary and Key Secondary Analyses Of Rifaximin in the Treatment of Non-Constipation Irritable Bowel Syndrome in Two Phase 3 Trials (Target 1 and Target 2)
...Phase 3, randomized, double-blind, placebo-controlled, multicenter trials, TARGET 1 and TARGET 2, designed to evaluate the efficacy and safety of rifaximin 550 mg TID in the treatment of patients with non-constipation irritable bowel syndrome (non-C IBS). In each trial rifaximin versus placebo treated...
Clinical Trial Results (FDA) · More like this

Having trouble finding what you want?


MedNotes
Advertisement

(web3)